Efficacy of Tolvaptan in Elderly Patients with Heart Failure and Preserved Ejection Fraction

1. Tsuchihashi-Makaya M, Hamaguchi S, Kinugawa S, et al. Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction. Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J. 2009;73:1893-1900.10.1253/circj.CJ-09-0254Search in Google Scholar

2. Hamaguchi S, Tsuchihashi-Makaya M, Kinugawa S, et al. Anemia is an independent predictor of long-term adverse outcomes in patients hospitalized with heart failure in Japan. A report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J. 2009;73:1901-1908.10.1253/circj.CJ-09-0184Search in Google Scholar

3. Suzuki S, Yoshihisa A, Yamaki T, et al. Acute heart failure volume control multicenter randomized (AVCMA) trial: comparison of tolvaptan and carperitide. J Clin Pharmacol. 2013;53:1277-1285. doi: 10.1002/jcph.197.10.1002/jcph.197Open DOISearch in Google Scholar

4. Ambrosy AP, Pang PS, Khan S, et al. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. Eur Heart J. 2013;34:835-843. doi: 10.1093/eurheartj/ehs444.10.1093/eurheartj/ehs444Open DOISearch in Google Scholar

5. Kinugawa K, Sato N, Inomata T, Shimakawa T, Iwatake N, Mizuguchi K. Efficacy and safety of tolvaptan in heart failure patients with volume overload. Circ J. 2014;78:844-852.10.1253/circj.CJ-14-0126Search in Google Scholar

6. Suzuki S, Yoshihisa A, Yamaki T, et al. Long-term effects and prognosis in acute heart failure treated with tolvaptan: the AVCMA trial. Biomed Res Int. 2014;2014:704289. doi: 10.1155/2014/704289.10.1155/2014/704289Search in Google Scholar

7. Kinugawa K, Inomata T, Sato N, et al. Effectiveness and adverse events of tolvaptan in octogenarians with heart failure. Interim analyses of Samsca Post-Marketing Surveillance In Heart faiLurE (SMILE study). Int Heart J. 2015;56:137-143. doi: 10.1536/ihj.14-332.10.1536/ihj.14-332Open DOISearch in Google Scholar

8. Kimura K, Momose T, Hasegawa T, et al. Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure. J Cardiol. 2016;67:399-405. doi: 10.1016/j.jjcc.2015.09.020.10.1016/j.jjcc.2015.09.020Search in Google Scholar

9. Ono Y, Takamatsu H, Inoue M, et al. Clinical effect of long-term administration of tolvaptan in patients with heart failure and chronic kidney disease. Drug Discov Ther. 2018;12:154-160. doi: 10.5582/ddt.2018.01007.10.5582/ddt.2018.01007Open DOISearch in Google Scholar

10. Felker GM, Mentz RJ, Cole RT, et al. Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure. J Am Coll Cardiol. 2017;69:1399-1406. doi: 10.1016/j.jacc.2016.09.004.10.1016/j.jacc.2016.09.004Search in Google Scholar

11. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971;285:1441-1446. doi: 10.1056/NEJM197112232852601.10.1056/NEJM197112232852601Open DOISearch in Google Scholar

12. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Kardiol Pol. 2016;74:1037-1147. doi: 10.5603/KP.2016.0141.10.5603/KP.2016.0141Open DOISearch in Google Scholar

13. Forman DE, Butler J, Wang Y, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004;43:61-67.10.1016/j.jacc.2003.07.031Search in Google Scholar

14. Krumholz HM, Chen YT, Vaccarino V, et al. Correlates and impact on outcomes of worsening renal function in patients > or =65 years of age with heart failure. Am J Cardiol. 2000;85:1110-1113.10.1016/S0002-9149(00)00705-0Search in Google Scholar

15. Inomata T, Ikeda Y, Kida K, et al. Effects of additive tolvaptan vs. increased furosemide on heart failure with diuretic resistance and renal impairment — results from the K-STAR study. Circ J. 2017;82:159-167. doi: 10.1253/circj.CJ-17-0179.10.1253/circj.CJ-17-0179Open DOISearch in Google Scholar

16. Matsue Y, Suzuki M, Torii S, et al. Prognostic impact of early treatment with tolvaptan in patients with acute heart failure and renal dysfunction. Int J Cardiol. 2016;221:188-193. doi: 10.1016/j.ijcard.2016.07.063.10.1016/j.ijcard.2016.07.063Open DOISearch in Google Scholar

17. Matsue Y, Ter Maaten JM, Suzuki M, et al. Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction. Clin Res Cardiol. 2017;106:802-812. doi: 10.1007/s00392-017-1122-1.10.1007/s00392-017-1122-1Open DOISearch in Google Scholar

18. Uemura Y, Shibata R, Takemoto K, et al. Safety and efficacy of long-term use of tolvaptan in patients with heart failure and chronic kidney disease. Circ J. 2017;81:1736-1738. doi: 10.1253/circj.CJ-17-055.10.1253/circj.CJ-17-055Open DOISearch in Google Scholar

19. Nakano Y, Mizuno T, Niwa T, et al. Impact of continuous administration of tolvaptan on preventing medium-term worsening renal function and long-term adverse events in heart failure patients with chronic kidney disease. Int Heart J. 2018;59:105-111. doi: 10.1536/ihj.16-625.10.1536/ihj.16-625Open DOISearch in Google Scholar

20. Kortebein P, Ferrando A, Lombeida J, Wolfe R, Evans WJ. Effect of 10 days of bed rest on skeletal muscle in healthy older adults. JAMA. 2007;297:1772-1774. doi: 10.1001/jama.297.16.1772-b.10.1001/jama.297.16.1772-bSearch in Google Scholar

21. Uemura Y, Shibata R, Takemoto K, et al. Prognostic impact of the preservation of activities of daily living on post-discharge outcomes in patients with acute heart failure. Circ J. 2018;82:2793-2799. doi: 10.1253/circj.CJ-18-0279.10.1253/circj.CJ-18-0279Open DOISearch in Google Scholar

22. Ueda K, Kasao M, Shimamura M, et al. Impact of oral treatment on physical function in older patients hospitalized for heart failure: a randomized clinical trial. PLoS One. 2016;11:e0167933. doi: 10.1371/journal.pone.0167933.10.1371/journal.pone.0167933Search in Google Scholar

23. Imamura T, Kinugawa K. Tolvaptan improves the long-term prognosis in patients with congestive heart failure with preserved ejection fraction as well as in those with reduced ejection fraction. Int Heart J. 2016;57:600-606. doi: 10.1536/ihj.16-023.10.1536/ihj.16-023Open DOISearch in Google Scholar

24. Lucas C, Johnson W, Hamilton MA, et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J. 2000;140:840-847. doi: 10.1067/mhj.2000.110933.10.1067/mhj.2000.110933Open DOISearch in Google Scholar

25. Lala A, McNulty SE, Mentz RJ, et al. Relief and recurrence of congestion during and after hospitalization for acute heart failure: insights from Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF). Circ Heart Fail. 2015;8:741-748. doi: 10.1161/CIRCHEARTFAILURE.114.001957.10.1161/CIRCHEARTFAILURE.114.001957Search in Google Scholar